Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADPT Adaptive Biotechnologies	$9.52 +2.3%	$8.30	$2.99 ▼ $10.28	$1.45B	1.75	1.58 million shs	1.76 million shs
EXAI Exscientia	$4.84	$4.97	$3.80 ▼ $6.49	$632.93M	0.83	659,594 shs	N/A
INBX Inhibrx	$13.56 -1.4%	$12.40	$10.80 ▼ $18.95	$196.30M	N/A	119,771 shs	76,321 shs
RGNX REGENXBIO	$8.68 -3.2%	$7.88	$5.04 ▼ $15.36	$435.39M	1.11	893,192 shs	830,369 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADPT Adaptive Biotechnologies	+2.26%	+6.61%	+29.35%	+15.25%	+165.92%
EXAI Exscientia	0.00%	0.00%	0.00%	0.00%	+3.64%
INBX Inhibrx	-1.38%	+5.44%	+9.98%	+2.34%	-60.25%
RGNX REGENXBIO	-3.23%	-10.61%	-9.68%	+32.12%	-38.48%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADPT Adaptive Biotechnologies	3.1928 of 5 stars	1.4	2.0	4.2	4.2	2.5	0.6
EXAI Exscientia	0.1575 of 5 stars	1.0	0.0	0.0	0.0	1.7	0.6
INBX Inhibrx	2.1084 of 5 stars	0.0	1.0	4.6	3.3	2.5	1.3
RGNX REGENXBIO	4.2239 of 5 stars	3.4	1.0	4.6	3.4	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADPT Adaptive Biotechnologies	2.83	Moderate Buy	$9.83	3.29% Upside
EXAI Exscientia	2.00	Hold	$5.00	3.31% Upside
INBX Inhibrx	2.00	Hold	N/A	N/A
RGNX REGENXBIO	2.83	Moderate Buy	$31.63	264.34% Upside

Current Analyst Ratings Breakdown

Latest EXAI, RGNX, INBX, and ADPT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2025	INBX Inhibrx	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
5/6/2025	ADPT Adaptive Biotechnologies	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$11.00 ➝ $13.00
5/5/2025	ADPT Adaptive Biotechnologies	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$7.00 ➝ $9.00
5/2/2025	ADPT Adaptive Biotechnologies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $10.00
4/17/2025	RGNX REGENXBIO	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$14.00 ➝ $12.00
3/21/2025	ADPT Adaptive Biotechnologies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$8.00 ➝ $9.00
3/20/2025	RGNX REGENXBIO	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$52.00 ➝ $52.00
3/18/2025	RGNX REGENXBIO	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$24.00
3/17/2025	RGNX REGENXBIO	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $34.00
3/14/2025	RGNX REGENXBIO	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$22.00 ➝ $24.00
3/14/2025	RGNX REGENXBIO	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$52.00 ➝ $52.00

(Data available from 5/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADPT Adaptive Biotechnologies	$189.53M	7.63	N/A	N/A	$1.37 per share	6.95
EXAI Exscientia	$25.60M	24.72	N/A	N/A	$2.54 per share	1.91
INBX Inhibrx	$200K	981.47	N/A	N/A	N/A	∞
RGNX REGENXBIO	$156.72M	2.78	N/A	N/A	$7.09 per share	1.22

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADPT Adaptive Biotechnologies	-$159.49M	-$0.96	N/A	N/A	N/A	-89.12%	-64.65%	-26.45%	8/7/2025 (Estimated)
EXAI Exscientia	-$181.56M	-$1.51	N/A	N/A	N/A	-882.09%	-49.10%	-33.13%	N/A
INBX Inhibrx	-$154.96M	$116.75	0.12	N/A	N/A	N/A	-113.74%	-80.56%	6/16/2025 (Estimated)
RGNX REGENXBIO	-$263.49M	-$3.11	N/A	N/A	N/A	-283.19%	-70.65%	-41.68%	8/7/2025 (Estimated)

Latest EXAI, RGNX, INBX, and ADPT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q4 2024	INBX Inhibrx	-$2.55	-$2.80	-$0.25	-$2.80	N/A	N/A
5/12/2025	Q1 2025	RGNX REGENXBIO	$0.41	$0.12	-$0.29	$0.12	$105.35 million	$89.01 million
5/1/2025	Q1 2025	ADPT Adaptive Biotechnologies	-$0.28	-$0.20	+$0.08	-$0.20	$42.13 million	$52.44 million
3/17/2025	Q4 2024	INBX Inhibrx	-$2.88	-$3.09	-$0.21	-$3.09	N/A	$0.10 million
3/13/2025	Q4 2024	RGNX REGENXBIO	-$1.27	-$1.01	+$0.26	-$1.01	$23.70 million	$21.21 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADPT Adaptive Biotechnologies	N/A	N/A	N/A	N/A	N/A
EXAI Exscientia	N/A	N/A	N/A	N/A	N/A
INBX Inhibrx	N/A	N/A	N/A	N/A	N/A
RGNX REGENXBIO	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADPT Adaptive Biotechnologies	N/A	2.89	2.81
EXAI Exscientia	0.06	4.54	4.54
INBX Inhibrx	N/A	4.70	4.70
RGNX REGENXBIO	N/A	3.05	3.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADPT Adaptive Biotechnologies	99.17%
EXAI Exscientia	41.58%
INBX Inhibrx	82.46%
RGNX REGENXBIO	88.08%

Insider Ownership

Company	Insider Ownership
ADPT Adaptive Biotechnologies	6.40%
EXAI Exscientia	16.40%
INBX Inhibrx	17.09%
RGNX REGENXBIO	12.79%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADPT Adaptive Biotechnologies	790	151.92 million	138.43 million	Optionable
EXAI Exscientia	280	130.77 million	109.32 million	Optionable
INBX Inhibrx	166	14.48 million	11.26 million	Optionable
RGNX REGENXBIO	370	50.16 million	43.04 million	Optionable

EXAI, RGNX, INBX, and ADPT Headlines

Recent News About These Companies

Millennium Management LLC Buys 1,061,187 Shares of REGENXBIO Inc. (NASDAQ:RGNX)

May 26, 2025 | marketbeat.com

BNP Paribas Financial Markets Acquires 75,652 Shares of REGENXBIO Inc. (NASDAQ:RGNX)

May 25, 2025 | marketbeat.com

Q2 Earnings Forecast for REGENXBIO Issued By Leerink Partnrs

May 24, 2025 | marketbeat.com

REGENXBIO Inc. (NASDAQ:RGNX) Shares Purchased by Jane Street Group LLC

May 23, 2025 | marketbeat.com

Regenxbio at RBC Conference: Strategic Moves and Clinical Progress

May 22, 2025 | investing.com

REGENXBIO FY2025 EPS Forecast Reduced by Chardan Capital

May 21, 2025 | marketbeat.com

REGENXBIO Inc.: REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million

May 20, 2025 | finanznachrichten.de

REGENXBIO announces royalty monetization agreement for up to $250M

May 20, 2025 | msn.com

REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million

May 19, 2025 | prnewswire.com

Point72 Asia Singapore Pte. Ltd. Makes New $447,000 Investment in REGENXBIO Inc. (NASDAQ:RGNX)

May 18, 2025 | marketbeat.com

Hudson Bay Capital Management LP Has $2.38 Million Position in REGENXBIO Inc. (NASDAQ:RGNX)

May 16, 2025 | marketbeat.com

REGENXBIO Inc. (NASDAQ:RGNX) Director Sells $162,961.82 in Stock

May 15, 2025 | insidertrades.com

US FDA accepts and grants priority review status to Regenxbio’s BLA for clemidsogene lanparvovec to treat Mucopolysaccharidosis II

May 15, 2025 | pharmabiz.com

Earnings Miss: REGENXBIO Inc. Missed EPS By 64% And Analysts Are Revising Their Forecasts

May 15, 2025 | finance.yahoo.com

FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment

May 14, 2025 | prnewswire.com

REGENXBIO Inc. (NASDAQ:RGNX) Shares Sold by Integral Health Asset Management LLC

May 14, 2025 | marketbeat.com

FDA Grants Regenxbio Priority Review for MPS II Gene Therapy Regulatory Application

May 13, 2025 | precisionmedicineonline.com

Regenxbio stock rises on FDA’s priority review for MPS II therapy

May 13, 2025 | investing.com

REGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II

May 13, 2025 | prnewswire.com

Cubist Systematic Strategies LLC Makes New $2.79 Million Investment in REGENXBIO Inc. (NASDAQ:RGNX)

May 13, 2025 | marketbeat.com

Brevan Howard Capital Management LP Buys Shares of 41,160 REGENXBIO Inc. (NASDAQ:RGNX)

May 13, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EXAI, RGNX, INBX, and ADPT Company Descriptions

Adaptive Biotechnologies NASDAQ:ADPT

$9.52 +0.21 (+2.26%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$9.64 +0.12 (+1.21%)

As of 05/30/2025 07:14 PM Eastern

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Exscientia NASDAQ:EXAI

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.

Inhibrx NASDAQ:INBX

$13.56 -0.19 (-1.38%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$13.44 -0.12 (-0.85%)

As of 05/30/2025 06:16 PM Eastern

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

REGENXBIO NASDAQ:RGNX

$8.68 -0.29 (-3.23%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$8.92 +0.24 (+2.81%)

As of 05/30/2025 07:48 PM Eastern

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time